ImmunoMet Therapeutics Raises $5.0 million in a Series B Financing
Company to Advance Development of IM156, an OXPHOS Inhibitor, and Immuno-Oncology Platform
Houston, TX, March 7, 2017 – ImmunoMet Therapeutics, a development stage biotechnology company
focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today
announced that the Company has raised $5.0 million in a Series B financing with participation from Intervest,
SL Investment, NHN Investment along with the Series A investors Mirae Asset Venture Investments, GNTech
and Dr. Sung-wuk Kim, founder, Chairman and CEO of ImmunoMet.
“This financing will fund the Company’s Phase 1 clinical study for IM156 and the preclinical studies of our
immuno-oncology program that is focused on inhibiting immune suppressor cells. We are enthusiastic about
the potential opportunities in our pipeline to provide life-saving medicines for patients, especially those with
drug resistant cancers,” said Benjamin R. Cowen, Chief Operating Officer of ImmunoMet.
The Company’s lead molecule, IM156, an OXPHOS inhibitor, is expected to enter a Phase 1 clinical trial in the
second quarter of 2017. IM156 has demonstrated positive in vivo results in resistant brain and lung tumors in
preclinical studies. Additionally, the Company’s immuno-oncology program, IM188, is being developed in
combination with immunotherapies, including an anti-PD1. The IM188 program is in late stage lead-
optimization and has demonstrated tumor regression in a renal cancer model.
Dr. Sung-wuk Kim, CEO of ImmunoMet, said, “In addition to the completion of this Series B round, the
Company has made significant progress including the strengthening of our management team, the formation
of our world-renowned scientific advisory board, and establishing our headquarters and research and
development facilities at JLABS in Houston TX.”
About ImmunoMet Therapeutics
ImmunoMet Therapeutics, a private, early stage biotechnology company, is dedicated to developing innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients. The Company, a spinoff of HanAll, a Korean biopharma company, is headquartered at JLABS in Houston. ImmunoMet’s R&D program is focused on utilizing cellular metabolism to develop novel cancer and immuno-oncology therapies, which include cancer metabolism designed to disrupt a tumor’s energy source using OXPHOS inhibitors to treat drug resistant and relapse cancers and immuno-oncology targeting immune suppressor cells to enhance the response of current immunotherapies. For more information about the Company, please visit www.immunomet.com.
Benjamin R. Cowen: Chief Operating Officer, 215-527-1312, firstname.lastname@example.org
Joseph T. Schepers: 770-558-5517, email@example.com